287737-63-7

Upstream product

• 582-52-5 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 2847-00-9 1,2:5,6-di-O-isopropylidene-α-D-hexofuran-3-ulose 
• 233266-76-7 (3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde 
• 27200-84-6 methyl triphenylphosphonium bromide 
• 22331-21-1 1,2:5,6-di-O-isopropylidene-3-O-benzyl-α-D-allofuranose 
• 100-39-0 benzyl bromide 
• 2595-05-3 Diacetone D-glucose 
• 63593-03-3 1,2-O-isopropylidene-3-O-benzyl-4-hydroxymethyl-α-D-ribofuranose 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 153186-10-8 ((3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol 
• 57099-04-4 3-O-benzyl-1,2-O-isopropylidene-α-D-allofuranose 

Downstream Products

• 945382-96-7 1-[4-C-allyl-3,5-di-O-benzyl-2-O-acetyl-β-D-ribofuranosyl]-thymine 
• 945382-98-9 1-[4-C-allyl-3,5-di-O-benzyl-2-O-phenoxythiocarbonyl-β-D-ribofuranosyl]-thymine 
• 945383-09-5 3,5-di-O-benzyl-4-C-hydroxypropyl-1,2-O-isopropylidene-α-D-ribofuranose 
• 945383-12-0 3,5-di-O-benzyl-4-C-penten-yl-1,2-O-isopropylidene-α-D-ribofuranose 
• 945383-14-2 C₃₀H₃₄N₂O₇ 
• 945383-16-4 1-[3,5-di-O-benzyl-4-C-penten-yl-2-hydroxy-β-D-ribofuranosyl]-thymine 
• 945383-18-6 1-[3,5-di-O-benzyl-4-C-penten-yl-2-O-phenoxythiocarbonyl-β-D-ribofuranosyl]-thymine 
• 945383-20-0 (1R,2R,5R,7R,8S)-8-benzyloxy-5-benzyloxymethyl-2-methyl-7-(thymin-1-yl)-6-oxa-bicyclo[3.2.1]octane 
• 945383-24-4 (1R,2R,5R,7R,8S)-5-(4,4'-dimethoxytrityloxymethyl)-8-hydroxy-2-methyl-7-(thymin-1-yl)-6-oxa-bicyclo[3.2.1]octane 
• 287737-61-5 C₂₄H₂₈O₆ 
• 945382-92-3 4-C-allyl-3,5-di-O-benzyl-1,2-O-isopropylidene-α-D-ribofuranose 
• 945382-94-5 C₂₆H₃₀O₇ 
• 1610605-74-7 (2R,3R,4S,5R)-2-(2-amino-6-chloro-9H-purin-9-yl)-4-(benzyloxy)-5-((benzyloxy)methyl)-5-(2-(tosyloxy)ethyl)tetrahydrofuran-3-yl acetate 
• 1610605-75-8 2-amino-9-((1R,5R,7R,8S)-8-(benzyloxy)-5-((benzyloxy)methyl)-2,6-dioxabicyclo[3.2.1]octan-7-yl)-1H-purin-6(9H)-one 

Relevant academic research and scientific papers

METHOD FOR PRODUCING NUCLEOSIDE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a practical method for producing a nucleoside derivative that is applied to RNA pharmaceuticals or the like. SOLUTION: The present invention provides a method for producing a nucleotide derivative represented by a compound

4'-VINYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS RNA REPLICATION

The application discloses compounds of Formula I wherein the variable substituents are as defined herein. The compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I are useful for the treatment of diseases mediated by RSV.

PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS

Provided herein are formulations, methods and substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.

Synthesis of 2′-O,4′-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase

The synthesis of 2′-O,4′-C-methylene-bridged bicyclic guanine ribonucleosides bearing 2′-C-methyl or 5′-C-methyl modifications is described. Key to the successful installation of the methyl functionality in both cases was the use of a one-pot oxidation-Grignard procedure to avoid formation of the respective unreactive hydrates prior to alkylation. The 2′-C-methyl- and 5′-C-methyl-modified bicyclic guanosines were evaluated, along with the known uracil-, cytosine-, adenine-, guanine-LNA and guanine-ENA nucleosides, as potential antiviral agents and found to be inactive in the hepatitis C virus (HCV) cell-based replicon assay. Examination of the corresponding nucleoside triphosphates, however, against the purified HCV NS5B polymerase indicated that LNA-G and 2′-C-methyl-LNA-G are potent inhibitors of both 1b wild type and S282T mutant enzymes in vitro. Activity was further demonstrated for the LNA-G-triphosphate against HCV NS5B polymerase genotypes 1a, 2a, 3a and 4a. A phosphorylation by-pass prodrug strategy may be required to promote anti-HCV activity in the replicon assay.

BRIDGED ARTIFICIAL NUCLEOSIDE AND NUCLEOTIDE

It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity

FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'- CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER

Compounds (1, 2, 3, 4) according to the formulae shown below: (Formula 1, 2, 3,4). For General Formula1-4:N=1-Thyminyl,9-Adeninyl,9-Guaninyl,1-Cytosinyl, 5-methyl-1-cytosinyl, 5-trifluoromethyl-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-tr

Five- and six-membered conformationally locked 2′,4′- carbocyclic ribo-thymidines: Synthesis, structure, and biochemical studies

Two unusual reactions involving the 5-hexenyl or the 6-heptenyl radical cyclization of a distant double bond at C4′ and the radical center at C2′ of the ribofuranose ring of thymidine have been used as key steps to synthesize North-type conformationally c

Synthesis and properties of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides

Novel bicyclo nucleosides, 2′-O,4′-C-ethylene nucleosides and 2′-O,4′-C-propylene nucleosides, were synthesized as building blocks for antisense oligonucleotides to further optimize the 2′-O,4′-C-methylene-linkage of bridged nucleic acids (2′,4′-BNA) or l

2′-O,4′-C-ethylene-bridged nucleic acids (ENA): Highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug

To develop antisense oligonucleotides, novel nucleosides, 2′-O,4′-C-ethylene nucleosides and their corresponding phosphoramidites, were synthesized as building blocks. The 1H NMR analysis showed that the 2′-O,4′-C-ethylene linkage of these nucleosides restricts the sugar puckering to the N-conformation as well as the linkage of 2′-O,4′-C-methylene nucleosides which are known as bridged nucleic acids (BNA) or locked nucleic acids (LNA). The ethylene-bridged nucleic acids (ENA) showed a high binding affinity for the complementary RNA strand (ΔTm = + 5.2 °C/modification) and were more nuclease-resistant than natural DNA and BNA/LNA. These results indicate that ENA have better properties as antisense oligonucleotides than BNA/LNA.